Neuronetics Receives 510(k) Clearance For Obsessive-Compulsive Disorder Motor Threshold Cap For Neurostar Advanced Therapy
Portfolio Pulse from Benzinga Newsdesk
Neuronetics has received 510(k) clearance from the FDA for its Obsessive-Compulsive Disorder (OCD) Motor Threshold Cap for NeuroStar Advanced Therapy, allowing the company to expand its treatment options.
June 12, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neuronetics received FDA 510(k) clearance for its OCD Motor Threshold Cap for NeuroStar Advanced Therapy, potentially boosting its market presence.
The FDA 510(k) clearance allows Neuronetics to market and sell its OCD Motor Threshold Cap for NeuroStar Advanced Therapy. This expands the company's treatment options and could lead to increased revenue and market presence. As a result, the stock price is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100